Zurück zu Projekte

13071.1 PFLS-LS

13071.1 PFLS-LS

Zusammenfassung

Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Weitere Texte

Abstract

This R&D/Clinical project aims at evaluating the potential effect of a new therapeutic compound, called MDPK67b, for treatment of hormone refractory prostate cancer in a first in man clinical trial in healthy volunteers. The safety and tolerability of MDPK67b in humans will be established to assess its pharmacokinetic profile (PK) in escalating single and repeated doses, and to collect pharmacodynamic (PD) data. It will be important to confirm its biochemical efficacy profile and design rationally a phase II proof of concept trial in patients. Relevant ex vivo tests for determination of drug PD will be developed and used in the clinical trial.

Beteiligte

Christoph Kündig

Wirtschaftspartner

christoph.kundig@med-discovery.com

Med Discovery SA Christoph Kündig Route de la Corniche 4 1066 Epalinges VD CH

Thierry Buclin

Kontaktperson

thierry.buclin@chuv.ch

CHUV Centre Hospitalier Universitaire Va Thierry Buclin Rue du Bugnon 17 1011 Lausanne VD CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2013-02-28
Enddatum
2016-09-30
Bewilligte Gesamtkosten
CHF 482878.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%